Astellas Pharma announced it is acquiring Ocata Therapeutics for $379M. Headquartered in Tokyo, Japan, Astellas is the second largest drug company in Japan, generating over $10 billion in drug sales last year, while Ocata is headquartered in Marlborough, Massachusetts. Astellas’ cash flow is essential, because the company has agreed to pay $8.50 a share for Ocata, a 79% premium over the stock price last Friday. [Read more…]
Cynata Introduces a Scalable Mesenchymal Stem Cell (MSC) Manufacturing Platform
Cynata Therapeutics is a regenerative medicine company,  listed on the Australian exchange with the ticker symbol CYP (ASX: CYP). The company recently broke onto the regenerative medicine scene by developing Cymerus™, a therapeutic stem cell platform technology that utilizes discoveries made at the University of Wisconsin-Madison (UWM).
UWM is a world-renowned leader in stem cell research that is best known for the work by Professor James Thomson’s research team, which succeeded in first isolating human embryonic stem cells (hESCs) in 1998 and successfully producing induced pluripotent stem cells (iPSCs) from human adult cells in 2007.
Cynata co-founder, Professor Igor Slukvin, was a member of the team that conducted UWM’s pioneering iPSC research. UWM is also infamous for its strong patent positions pertaining to the process of human embryonic stem cell (hESC) derivation. [Read more…]
My Story: Founder of a Stem Cell Market Research Firm and a Stem Cell Patient
For nearly two decades, I have studied stem cells, including technology and research advances, as well as market trends. I have been fascinated with them for most of my adult life, founding BioInformant as the first and only market research firm to specialize in the stem cell industry.
As a result of this decision, I have had the honor of serving thousands clients from across the stem cell industry and been interviewed by the Wall Street Journal, Los Angeles Business Journal, and Vogue Magazine.
However, it was only recently that I experienced the power of stem cells to impact my own life and health.
Induced Pluripotent Stem Cell (iSPC) News Round-Up| January 2015
The induced pluripotent stem cell (iPSC) industry is a rapidly evolving area.  Since the discovery of iPSCs in 2006, there have been a number of important market events that have occurred, including the first ever clinical trial in humans that was initiated in August 2013 to investigate iPSC-derived cell sheets for restoring vision, as well as large funding awards, major initial public offerings (IPOs), critical patent challenges, and more. [Read more…]
- « Previous Page
- 1
- …
- 16
- 17
- 18